Shimadzu Scientific Instruments, Ceres Nanosciences, and Nonlinear Dynamics have partnered to launch the Nanotrap Biomarker Discovery Platform for the enrichment, preservation, and screening of low-level biomarkers directly from complex biological samples.
The platform integrates Ceres’ Nanotrap technology with Shimadzu’s Axima MALDI mass specs for screening and identification. Nonlinear Dynamics’ Progenesis MALDI software generates high-quality proteomics data to define biomarkers, improving reliability and reproducibility of results, according to Shimadzu.
Nanotraps are core hydrogel particles with porous interiors and size exclusion shells. By providing fractionation, concentration, and protection of low-level biomarkers directly from complex biological fluids, the Nanotrap Biomarkers Discovery Platform detects biomarkers with low sensitivity and specificity, Shimadzu said in a statement. Such biomarkers currently have limited clinical use for early disease detection.
Proxeon this week launched the second generation of its Easy-nLC instrument, which provides researchers “the opportunity to significantly improve system productivity as a result of a new autosampler and upgraded software.”
The new platform uses a so-called “split-free” configuration for improved sensitivity, reproducibility, and system stability, Proxeon said in a statement. The new autosampler has a fully insulated, refrigerated compartment with increased capacity for sample vials and wash solvents, allowing the system to run unattended for longer periods of time than previously possible.
Also, a new “intelligent flow control” feature enables runs to be preprogrammed to user-defined pressure limits, “ensuring rapid build-up of pressure and flow, speeding up equilibrium and sample-loading steps and eliminating the interruptions that can occur due to pressure fluctuations,” Proxeon said.
Silicon Kinetics this week launched new SKI Pro biosensor chips with surface chemistries NTA-Ni, Protein A, and Protein G.
The NTA-Ni chemistry is for His-tagged proteins, while Protein A and Protein G are for coupling antibodies. The San Diego-based firm also has biosensors with 3D nanoporous silicon chips with carboxyl, streptavidin, and benzaldehyde surface chemistries.
According to the company, SKI Pro is the “world’s only label-free biomolecular interaction analysis platform, which allows high-throughput ranking in multiwall plates and data-rich kinetic measurements in flow cells.”
Kinexus introduced its Protein Kinase Microarray with 200 recombinant human protein kinases for screening.
The arrays are designed for drug screening, substrate profiling, and kinase interaction discovery. According to Kinexus, the arrays allow clients to inexpensively assay the abilities of their lead compounds to inhibit any of the 200 protein kinases for as low as $1.65 per kinase with triplicate measurements, compared to $4 to $5 per kinase tracked with current methods commonly used for such measurements.